Intratumour heterogeneity in urologic cancers: From molecular evidence to clinical implications

European Urology

Volumn 67, Issue 4, 2015, Pages 729-737

  Gerlinger, Marco ^a,b   Catto, James W ^c   Orntoft, Torben F ^d   Real, Francisco X ^e,f   Zwarthoff, Ellen C ^g   Swanton, Charles ^h,i  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Structural Biology and Biocomputing Programme   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Bladder cancer; Cancer evolution; Genetics; Personalised medicine; Prostate cancer; Renal cancer; Tumour heterogeneity

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR MARKER;

BLADDER CARCINOMA; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLONE; DRUG TARGETING; EVOLUTION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; INTRATUMOR HETEROGENEITY; KIDNEY CARCINOMA; MEDICAL TECHNOLOGY; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PUBLICATION; REVIEW; SEPARATION TECHNIQUE; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA; TRANSLATIONAL RESEARCH; TUMOR BIOPSY; URINARY TRACT CANCER; DISEASE COURSE; FEMALE; GENETICS; MALE; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; URINARY TRACT TUMOR;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; FEMALE; GENETIC HETEROGENEITY; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; UROLOGIC NEOPLASMS;

EID: 84923097970     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.04.014     Document Type: Review

References (54)

1. M.F. Berger, M.S. Lawrence, and F. Demichelis The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
2. Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 2013 43 49
3. C. Balbas-Martinez, A. Sagrera, and E. Carrillo-de-Santa-Pau Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy Nat Genet 45 2013 1464 1469
4. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
5. P.J. Fialkow Clonal origin of human tumors Ann Rev Med 30 1979 135 143
6. P.C. Nowell The clonal evolution of tumor cell populations Science 194 1976 23 28
7. R.A. Burrell, N. McGranahan, J. Bartek, and C. Swanton The causes and consequences of genetic heterogeneity in cancer evolution Nature 501 2013 338 345
8. A. Marusyk, V. Almendro, and K. Polyak Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12 2012 323 334
9. S. Nik-Zainal, P. Van Loo, and D.C. Wedge The life history of 21 breast cancers Cell 149 2012 994 1007
10. T. Voet, P. Kumar, and P. Van Loo Single-cell paired-end genome sequencing reveals structural variation per cell cycle Nucleic Acids Res 41 2013 6119 6138
11. C. Zong, S. Lu, A.R. Chapman, and X.S. Xie Genome-wide detection of single-nucleotide and copy-number variations of a single human cell Science 338 2012 1622 1626
12. E. Heitzer, M. Auer, and C. Gasch Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing Cancer Res 73 2013 2965 2975
13. M. Murtaza, S.J. Dawson, and D.W. Tsui Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112
14. M. Gerlinger, S. Horswell, and J. Larkin Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing Nat Genet 46 2014 225 233
15. P. Martinez, N.J. Birkbak, and M. Gerlinger Parallel evolution of tumour subclones mimics diversity between tumours J Pathol 230 2013 356 364
16. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
17. A.R. Brannon, A. Reddy, and M. Seiler Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns Genes Cancer 1 2010 152 163
18. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
19. M. Hoglund On the origin of syn- and metachronous urothelial carcinomas Eur Urol 51 2007 1185 1193 discussion 1193
20. B. Czerniak, V. Chaturvedi, and L. Li Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer Oncogene 18 1999 1185 1196
21. A.A. van Tilborg, A. de Vries, M. de Bont, L.E. Groenfeld, T.H. van der Kwast, and E.C. Zwarthoff Molecular evolution of multiple recurrent cancers of the bladder Hum Mol Genet 9 2000 2973 2980
22. E. Letouze, Y. Allory, M.A. Bollet, F. Radvanyi, and F. Guyon Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis Genome Biol 11 2010 R76
23. S.J. Diaz-Cano, A. Blanes, J. Rubio, A. Matilla, and H.J. Wolfe Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder Lab Invest 80 2000 279 289
24. B.W. van Rhijn, T.H. van der Kwast, and A.N. Vis FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma Cancer Res 64 2004 1911 1914
25. A.A. Bakkar, H. Wallerand, and F. Radvanyi FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108 8112
26. L.C. Kompier, M.N. van der Aa, and I. Lurkin The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour J Pathol 218 2009 104 112
27. H. Kawanishi, T. Takahashi, and M. Ito Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation Br J Cancer 97 2007 260 266
28. S. Hernandez, E. Lopez-Knowles, and J. Lloreta FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis Clin Cancer Res 11 2005 5444 5450
29. R. Carretero, T. Cabrera, and H. Gil Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells Int J Cancer 129 2011 839 846
30. C.D. Morrison, P. Liu, and A. Woloszynska-Read Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer Proc Natl Acad Sci U S A 111 2014 E672 E681
31. L.C. Kompier, I. Lurkin, M.N. van der Aa, B.W. van Rhijn, T.H. van der Kwast, and E.C. Zwarthoff FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy PLoS One 5 2010 e13821
32. L. Dyrskjot, T. Reinert, and A. Novoradovsky Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR Br J Cancer 107 2012 1392 1398
33. T.C. Zuiverloon, M.N. van der Aa, and T.H. van der Kwast Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer Clin Cancer Res 16 2010 3011 3018
34. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
35. M. Karavitakis, H.U. Ahmed, P.D. Abel, S. Hazell, and M.H. Winkler Tumor focality in prostate cancer: implications for focal therapy Nat Rev Clin Oncol 8 2011 48 55
36. R. Arora, M.O. Koch, J.N. Eble, T.M. Ulbright, L. Li, and L. Cheng Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate Cancer 100 2004 2362 2366
37. S.C. Baca, D. Prandi, and M.S. Lawrence Punctuated evolution of prostate cancer genomes Cell 153 2013 666 677
38. L.K. Boyd, X. Mao, and L. Xue High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer Genes Chromosomes Cancer 51 2012 579 589
39. C. Ibeawuchi, H. Schmidt, and R. Voss Genome-wide investigation of multifocal and unifocal prostate cancer - are they genetically different? Int J Mol Sci 14 2013 11816 11829
40. J. Lindberg, D. Klevebring, and W. Liu Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins Eur Urol 63 2013 347 353
41. M. Barry, S. Perner, F. Demichelis, and M.A. Rubin TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications Urology 70 2007 630 633
42. G. Attard, C. Jameson, and J. Moreira Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity J Clin Pathol 62 2009 373 376
43. M. Yoshimoto, K. Ding, and J.M. Sweet PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade Mod Pathol 26 2013 435 447
44. W. Liu, S. Laitinen, and S. Khan Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer Nat Med 15 2009 559 565
45. M.P. Roudier, L.D. True, and C.S. Higano Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone Hum Pathol 34 2003 646 653
46. M.C. Haffner, T. Mosbruger, and D.M. Esopi Tracking the clonal origin of lethal prostate cancer J Clin Invest 123 2013 4918 4922
47. C.E. Barbieri, F. Demichelis, and M.A. Rubin The lethal clone in prostate cancer: redefining the index Eur Urol 66 2014 395 397
48. C. Ruiz, E. Lenkiewicz, and L. Evers Advancing a clinically relevant perspective of the clonal nature of cancer Proc Natl Acad Sci U S A 108 2011 12054 12059
49. A.M. Aparicio, A.L. Harzstark, and P.G. Corn Platinum-based chemotherapy for variant castrate-resistant prostate cancer Clin Cancer Res 19 2013 3621 3630
50. J.M. Mosquera, H. Beltran, and K. Park Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer Neoplasia 15 2013 1 10
51. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
52. E. Heitzer, P. Ulz, J. Belic, and S. Gutschi Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing Genome Med 5 2013 30
53. D.T. Miyamoto, R.J. Lee, and S.L. Stott Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer Cancer Discov 2 2012 995 1003
54. T.A. Yap, M. Gerlinger, P.A. Futreal, L. Pusztai, and C. Swanton Intratumor heterogeneity: seeing the wood for the trees Sci Transl Med 4 2012 127ps10